Advanced disease therapeutics using engineered living drug delivery systems

Area of Science:

• Biomaterials Science
• Nanotechnology
• Oncology

Background:

• Biological barriers hinder nanotherapeutic delivery, reducing efficacy in diseases like cancer.
• Current nanomedicine strategies often fail to overcome these obstacles, leading to poor drug accumulation and biodistribution.
• Nanomaterials (NMs) offer precise control over drug delivery and release, crucial for targeted cancer therapy.

Purpose of the Study:

• To review biological barriers limiting cancer nanotherapeutic delivery.
• To evaluate how stimuli-responsive NMs address these limitations for improved cancer treatment.
• To analyze the design, synthesis, and delivery strategies of stimuli-responsive NMs.

Main Methods:

• Systematic analysis of stimuli-responsive nanomaterial design and synthesis.
• Evaluation of various nanomaterial classes (polymeric, lipid-based, inorganic, hybrid).
• Exploration of functionalization approaches and diverse delivery strategies.

Main Results:

• Stimuli-responsive NMs leverage exogenous and endogenous triggers to enhance therapeutic specificity and reduce off-target effects.
• These NMs amplify drug activity within pathological microenvironments.
• Advances span material classes, functionalization, and delivery mechanisms.

Conclusions:

• Stimuli-responsive NMs show significant promise for precision oncology, enabling patient-specific therapies.
• Further research is needed to address challenges in biocompatibility, scalability, and clinical translation.
• Refining stimulus-triggered mechanisms will drive innovation in next-generation nanomedicine for enhanced cancer treatment efficacy and safety.